Anthracyclines News and Research

RSS
FDA approves APP Pharmaceuticals' Idarubicin HCI injection

FDA approves APP Pharmaceuticals' Idarubicin HCI injection

Combining two chemotherapy drugs with Herceptin shows promise for metastatic HER2+ breast cancer

Combining two chemotherapy drugs with Herceptin shows promise for metastatic HER2+ breast cancer

Gene alterations associated with response to anthracycline therapy for breast cancer

Gene alterations associated with response to anthracycline therapy for breast cancer

Researchers show how anthracycline class of chemotherapeutics block blood vessel growth, slow cancer spread

Researchers show how anthracycline class of chemotherapeutics block blood vessel growth, slow cancer spread

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Lapatinib benefits women with HER2-positive breast cancer

Lapatinib benefits women with HER2-positive breast cancer

Reduced dose anthracycline post-breast cancer surgery has no effect on outcome

Reduced dose anthracycline post-breast cancer surgery has no effect on outcome

Herceptin and chemotherapy improves response rates without major adverse effects in HER2 breast cancer

Herceptin and chemotherapy improves response rates without major adverse effects in HER2 breast cancer

Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy

Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy

Cardiac effects associated with breast cancer treatment appear lower

Cardiac effects associated with breast cancer treatment appear lower

Anthracyclines improve survival in HER2-positive breast cancer patients

Anthracyclines improve survival in HER2-positive breast cancer patients

Taxol-type drugs give slight boost to survival rates in early breast cancer

Taxol-type drugs give slight boost to survival rates in early breast cancer

Sea-squirt derived drug trabectedin shows promise as cancer treatment

Sea-squirt derived drug trabectedin shows promise as cancer treatment

Tykerb (lapatinib) - new anti-cancer treatment approved

Tykerb (lapatinib) - new anti-cancer treatment approved

Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma

Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma

Study indicates heart damage from some cancer drugs worsens over the years

Study indicates heart damage from some cancer drugs worsens over the years

HERA trial continues to demonstrate significant patient benefits from Herceptin

HERA trial continues to demonstrate significant patient benefits from Herceptin

Genes variations raise risk of heart disease after treatment for childhood cancer

Genes variations raise risk of heart disease after treatment for childhood cancer

Gene amplification could guide treatment for high-risk breast cancer

Gene amplification could guide treatment for high-risk breast cancer

Great news for breast cancer patients

Great news for breast cancer patients